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ntroduction
he burden of cardiovascular disease (CVD) among pa-
ients with diabetes is substantial. Individuals with diabetes
re at two- to fourfold increased risk of cardiovascular events
ompared with age- and sex-matched individuals without
iabetes. In diabetic patients over the age of 65 years, 68%
f deaths are from coronary heart disease (CHD) and 16%
re from stroke (1). A number of mechanisms for the
ncreased cardiovascular risk with diabetes have been pro-
osed, including increased tendency toward intracoronary
hrombus formation (2), increased platelet reactivity (3),
nd worsened endothelial dysfunction (4).
The increased risk for cardiovascular events and mortality
n patients with diabetes has led to considerable interest in
dentifying effective means for cardiovascular risk reduction.
spirin has been shown to be effective in reducing cardio-
vascular morbidity and mortality in high-risk patients with
myocardial infarction (MI) or stroke (secondary prevention)
(5). The Food and Drug Administration has not approved
aspirin for use in primary prevention, and its net benefit
among patients with no previous cardiovascular events is
more controversial, for both patients with and without a
history of diabetes (5). The U.S. Preventive Services Task
Force recently updated its recommendation about aspirin
use for primary prevention. The Task Force recommended
encouraging aspirin use in men age 45 to 79 years and
women age 55 to 79 years and not encouraging aspirin use
in younger adults. They did not differentiate their recom-
mendations based on the presence or absence of diabetes
(6,7).
In 2007, the American Diabetes Association (ADA) and
the American Heart Association (AHA) jointly recom-
mended that aspirin therapy (75 to 162 mg/day) be used as
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June 22, 2010:2878–86 Aspirin for Primary Prevention in Diabetesprimary prevention strategy in those with diabetes at
ncreased cardiovascular risk, including those who are over
0 years of age or who have additional risk factors (family
istory of CVD, hypertension, smoking, dyslipidemia, or
lbuminuria) (8). These recommendations were derived
rom several older trials that included relatively small num-
ers of patients with diabetes. Results of two recent ran-
omized controlled trials of aspirin performed specifically in
atients with diabetes raised questions about the efficacy of
spirin for primary prevention in diabetes (9,10).
Because of the scope of the problem of CVD in patients
ith diabetes and the conflicting evidence about the efficacy
f aspirin for primary prevention in people with diabetes,
he ADA, AHA, and the American College of Cardiology
oundation (ACCF) convened a group of experts to review
nd synthesize the available evidence and use this informa-
ion to create updated recommendations. The group con-
idered and organized this report around the following
uestions:
. What is the evidence regarding aspirin to prevent initial
cardiovascular events in people with diabetes?
. How can we reconcile the results of the different primary
prevention trials?
. What are the risks of aspirin, and are these similar or
different for people with diabetes compared to those
without?
. What do we know about the recommended dosage or
dosage range?
. How can we integrate potential benefits and risks of
aspirin to determine which patients with diabetes should
receive aspirin for the primary prevention of cardiovas-
cular events?
. What are the needs for future research?
. What Is the Evidence Regarding Aspirin
o Prevent Initial Cardiovascular Events in
eople With Diabetes?
everal randomized trials have examined the effect of aspirin
or primary prevention of cardiovascular events and have
ncluded patients with diabetes (Table 1). In this section, we
xamine those findings with respect to the ability of aspirin
o prevent cardiovascular events, which typically include
schemic or CHD events (MI, sometimes unstable angina),
troke, and vascular death (usually sudden cardiac death or
eath from stroke).
Six trials—British Medical Doctors (BMD) (11), Physi-
ians’ Health Study (PHS) (12), Thrombosis Prevention
rial (TPT) (13), Hypertension Optimal Treatment
HOT) (14), Primary Prevention Project (PPP) (15,16),
nd Women’s Health Study (WHS) (17)—were population-
ased and did not focus specifically on patients with
iabetes. The percentage of patients with diabetes in these
tudies ranged from 1% to 2% in TPT, BMD, and PHS to a2% in PPP. Two recent trials, the Japanese Prevention of
therosclerosis with aspirin for Diabetes (JPAD) (9) and
he Prevention of Progression of Arterial Disease and
iabetes (POPADAD) (10), and one older trial, the Early
reatment of Diabetic Retinopathy Study (ETDRS) (18),
nrolled only patients with diabetes. The available trials
except ETDRS) included mainly or exclusively patients
ith type 2 diabetes. ETDRS enrolled patients with both
ype 1 and type 2 diabetes (31% type 1, 31% type 2, and 38%
nclassified).
Three trials (BMD, PHS, and TPT) did not include any
omen, and one (WHS) focused solely on women. The
roportion of women in the remaining five trials varied from
4% to 56%. The dose of aspirin varied from 100 mg every
ther day to 650 mg daily. The nine trials ranged from 3.7
o 10.1 years in mean duration, with most extending to 4 to
years. Each of the trials excluded potential participants at
ncreased risk of gastrointestinal bleeding based on a history
f peptic ulcer disease. Therefore, the findings of this
eta-analysis, which are based on these trials, cannot be
eadily extended to patients with a history of gastrointestinal
leeding.
Only two of the nine trials reported on use of statins or
ther lipid-lowering therapy. In JPAD, statin use was 26%,
hile in PPP lipid-lowering therapy use was 13%. Three
rials (BMD, PHS, and ETDRS) were conducted prior to
he availability of statins, and TPT and HOT were con-
ucted well before the widespread use of statins for primary
revention. Rates of usage in the more recent POPADAD
r WHS trials were not reported.
The PHS trial enrolled 533 men with diabetes and found
41% relative risk (RR) reduction (RR 0.59, 95% CI 0.33
o 1.06) in fatal and nonfatal MI over 5 years for those
ssigned to 325 mg aspirin every other day compared with
hose assigned to placebo (12). The HOT trial examined
he effect of 75 mg of aspirin daily versus placebo in 18 000
atients ages 50 to 80 years, of whom 1501 had diabetes.
mong those with diabetes, the RR reduction for CHD
vents was 23% (RR 0.77, 95% CI 0.44 to 1.36) (14). The
PP trial enrolled 1031 patients with diabetes and found a
onsignificant reduction in the combined MI end point
fatal plus nonfatal MI) with 100 mg of aspirin daily compared
ith placebo (RR 0.50, 95% CI 0.17 to 1.46) (15).
The BMD and TPT studies enrolled relatively few
atients with diabetes and did not identify important
eductions in CVD risk for those with diabetes, but in each
ase confidence intervals were quite wide (11,13). The
HS trial, the only trial that focused exclusively on women
nd used the lowest dose of aspirin (100 mg every other
ay), did not find a reduction in risk for CHD with aspirin
verall or for the subset with diabetes (N1027; RR 1.34,
5% CI 0.85 to 2.12). They did, however, identify a
eduction in stroke with aspirin for women with diabetes
RR 0.45, 95% CI 0.25 to 0.82) (17).
Three trials focused on the effect of aspirin exclusivelymong patients with diabetes. The ETDRS trial examined
Table 1. Comparison of Primary Prevention Trials of Aspirin That Enrolled Patients With Diabetes (N11 787)
Study/Year (Ref.)
Aspirin Dose
(Study Design)
Follow-Up
(Years)
Number
Enrolled With
Diabetes
%
Female
Age (Years)
(Minimum/Mean) CHD Endpoint
CHD Endpoint
Event Rate
(Control vs. Aspirin)
10-Year
Extrapolated
CHD Event Ratesi RR (95% CI)ii
Stroke Events
for Aspirin vs. Control:
RR (95% CI)
PHS DM/1989 (12) 325 mg every other day
(2  2 factorial design
with 50 mg beta
carotene)
5.0 533 70 40/NA Fatal 
nonfatal MI
10.5% vs. 6.2%iii
(27/258 vs. 17/275)
21% vs. 12.4% 0.59 (0.33–1.06) 16 vs. 10:
1.50 (0.69–3.25)
ETDRS/1992 (18) 650 mg daily 5.0 3711 44 18/NA Fatal 
nonfatal MI
15.3% vs. 13.0%
(283/1855 vs. 241/1856)
30.6% vs. 26.0% 0.85 (0.73–1.00) 92 vs. 78:
1.18 (0.88–1.58)
PPP DM/2003iv (16) 100 mg daily (2  2 design
with 30 mg vitamin E)
3.7 1031 52 50/64 Fatal 
nonfatal MI
2.0% vs. 1.0%
(10/512 vs. 5/519)
5.4% vs. 2.7% 0.49 (0.17–1.43) 10 vs. 11:
0.90 (0.38–2.09)
WHS DM/2005 (17) 100 mg every other day
(2  2 factorial design
with 600 IU vitamin E
every other day)
10.1 1027 100 45/55 Fatal 
nonfatal MIv
5.9% vs. 7.9%
(29/494 vs. 42/533)
5.9% vs. 7.9% 1.34 (0.85–2.12) 15 vs. 31:
0.45 (0.25–0.82)
JPAD/2008 (10) 81–100 mg daily
(open label treatment
assignment, blinded
endpoint assessment)
4.4 2539 46 30/65 Fatal 
nonfatal MI
1.1% vs. 1.0%
(14/1277 vs. 12/1262)
2.5% vs. 2.3% 0.87 (0.40–1.87) 22 vs. 34:
0.65 (0.39–1.11)
POPADAD/2008 (9) 100 mg daily (2  2
factorial design
including anti-oxidants)
6.7 1276 56 40/60 CHD death 
nonfatal MI
12.9% vs. 13.9%
(82/638 vs. 89/638)
19.3% vs. 20.7% 1.09 (0.82–1.44) 37 vs. 50:
0.74 (0.49–1.12)
TPT DM/1998
(data from ATT) (5)
75 mg daily 6.7 68 0 45/58 MCE 15.4% vs. 13.8%
(6/39 vs. 4/29)
23.0% vs. 20.6% 0.90 (0.28–2.89) 1 vs. 2:
0.67 (0.06–7.06)
BMD/1988
(data from ATT) (5)
500 mg daily 5.6 101 0 50/NA MCE 18.8% vs. 18.8%
(6/32 vs. 13/69)
33.48% vs. 33.6% 1.00 (0.42–2.40) 3 vs. 1:
1.39 (0.15–12.86)
HOT DM/1998
(data from ATT) (5)
75 mg daily
(co-randomized to
one of three diastolic
BP goals)
3.8 1501 47 50/62 MCE 3.6% vs. 2.8%
(27/749 vs. 21/752)
9.5% vs. 7.3% 0.77 (0.44-1.36) 22 vs. 24:
0.91 (0.52-1.61)
i10-year extrapolated CHD event rate calculated by (10  study duration)  event rate. iiCalculated based on event counts. iiiValues slightly different from original PHS report based on updated ICD-9 coding information obtained by the ATT trialists. ivData used from
2003 PPP diabetic substudy (16); number with diabetes is discrepant from original PPP publication (15) due to continued enrollment and follow-up of diabetic patients beyond the original study period. vEvent rates slightly different than original 2005 report due to 11
extra MI/CHD deaths (6 in aspirin group and 5 in placebo) reported to the ATT study group vs. original publication.
ATT indicates Antithrombotic Trialists’ Collaboration; CHD, coronary heart disease; DM, diabetes mellitus; IU, international unit; MCE, major coronary event (CHD death  nonfatal MI  sudden death); MI, myocardial infarction; NA, not available; and RR, relative
risk.
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June 22, 2010:2878–86 Aspirin for Primary Prevention in Diabeteshe effect of 650 mg of aspirin daily versus placebo among
711 patients with type 1 or type 2 diabetes between ages 18
nd 70 years who had some degree of retinopathy. Approx-
mately one-half of participants reported some history of
VD, although it should be noted that the definition of
VD included the use of antihypertensive medication.
ewer than 10% had had a previous MI or stroke, and 9%
ad claudication. Intervention patients experienced a de-
reased risk of nonfatal or fatal MI (RR 0.85, 95% CI 0.73
o 1.00). In contrast, stroke occurred more frequently with
spirin, although the difference was not statistically signif-
cant (RR 1.18, 99% CI 0.88 to 1.58). Men appeared to
erive more benefit from aspirin than women for prevention
f MI (RR for men 0.74, 99% CI 0.54 to 1.00; RR for
omen 0.91, 99% CI 0.65 to 1.28), but this difference was
ot statistically significant and could represent a chance
nding (18).
The POPADAD trial studied whether aspirin and/or
ntioxidant therapy was more effective than placebo in
educing the incidence of cardiovascular events in patients
ith diabetes and asymptomatic peripheral arterial disease.
his randomized, multicenter, double-blind, placebo-
ontrolled trial involved 1276 adults over age 40 years with
ither type 1 or type 2 diabetes. All subjects had an ankle
rachial pressure index less than 0.99 but no symptomatic
VD. They were randomized in a 22 factorial design to
spirin 100 mg daily, an antioxidant supplement daily, both,
r neither. Two composite primary end points were 1) death
rom CHD or stroke, nonfatal MI or stroke, or amputation
bove the ankle for critical limb ischemia; and 2) death from
HD or stroke. Study medication discontinuation rates
ere high: 14% at 1 year and 50% at 5 years. Overall, 116
f 638 (18.2%) primary events occurred in patients assigned
o aspirin therapy versus 117 of 638 (18.3%) in those on
lacebo (HR 0.98, 95% CI 0.76 to 1.26). There were 43
HD or stroke deaths in the aspirin group and 35 in the
lacebo group (6.7% vs. 5.5%; HR 1.23, 95% CI 0.79 to
.93). The rates of a wide variety of secondary end points
nd adverse events also did not differ between groups.
utcomes were also similar with or without the antioxi-
ants; there was no interaction between the two active
herapies (10).
In JPAD, investigators examined the efficacy of low-dose
spirin for primary prevention of cardiovascular events in a
andomized, open-label trial conducted in 2539 Japanese
atients with type 2 diabetes but no history of CVD.
atients were assigned to either aspirin (81 to 100 mg daily)
r no aspirin and were followed for an average of 4.4 years.
he primary end point was a composite of fatal or nonfatal
schemic heart disease, fatal or nonfatal stroke, and periph-
ral arterial disease. A total of 154 events occurred: 68
5.4%) in the aspirin group and 86 (6.7%) in the nonaspirin
roup (HR 0.80, 95% CI 0.58 to 1.10). The combined
econdary end point of coronary and cerebrovascular mor-
ality occurred in 1 patient (stroke) in the aspirin group and
0 patients (five fatal MIs and five fatal strokes) in the wonaspirin group (HR 0.10, 95% CI 0.01 to 0.79). Other
econdary end points did not differ importantly between
roups. Overall, mortality occurred in 34 patients in the
spirin group and 38 patients in the nonaspirin group (HR
.90, 95% CI 0.57 to 1.14). According to prespecified
ubgroup analyses, however, in subjects over 65 years of age
n1363), the incidence of the primary end point was lower
ith aspirin (HR 0.68, 95% CI 0.46 to 0.99) (9).
In summary, the currently available evidence on aspirin
or CVD prevention includes three trials conducted specif-
cally in patients with diabetes and six other trials in which
atients with diabetes constitute subgroups within broader
rials of aspirin prophylaxis. No single trial provides defin-
tive results. As such, we sought, in question 2, to use
eta-analysis to try to reconcile the available data.
. How Can We Reconcile the
esults of the Different Trials?
n order to synthesize and reconcile the results of the
vailable trials, we examined existing meta-analyses of
spirin prevention trials (including those that focused on all
atients and those that examined only patients with diabe-
es) and performed new meta-analyses with updated data.
The Antithrombotic Trialists’ (ATT) Collaboration re-
ently published an individual patient-level meta-analysis of
he six large trials of aspirin for primary prevention in the
eneral population (5). These trials collectively enrolled over
5 000 participants, including almost 4000 with diabetes.
verall, the meta-analysis found that aspirin reduced the
isk of vascular events by 12% (RR 0.88, 95% CI 0.82 to
.94). The largest reduction was for nonfatal MI (RR 0.77,
5% CI 0.67 to 0.89). Aspirin had little effect on CHD
eath (RR 0.95, 95% CI 0.78 to 1.15) or total stroke (RR
.95, 95% CI 0.85 to 1.06). The net effect on total stroke
eflected a relative reduction in risk of ischemic stroke
14%) and a relative increased risk of hemorrhagic stroke
32%).
There was some evidence of a difference in aspirin effect
y sex. Aspirin reduced CHD events in men (RR 0.77, 95%
I 0.67 to 0.89) but not in women (RR 0.95, 95% CI 0.77
o 1.17). Conversely, aspirin had no effect on stroke in men
RR 1.01, 95% CI 0.74 to 1.39) but reduced stroke in
omen (RR 0.77, 95% CI 0.59 to 0.99). These potential
ifferences in effect by sex were of borderline statistical
ignificance, were affected strongly by the results of one trial
WHS), and cannot be considered definitive. Notably, sex
ifferences in aspirin’s effects have not been observed in
tudies of secondary prevention (5). The ATT collaborators
id not identify other clear sources of heterogeneity of
ffect, although there was some suggestion that current
mokers derived less benefit from aspirin than nonsmokers.
In the six trials examined by the ATT, the effect of aspirin
n major vascular events was similar for patients with and
ithout diabetes: RR 0.88, 95% CI 0.67 to 1.15, and RR
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Aspirin for Primary Prevention in Diabetes June 22, 2010:2878–86.87, 95% CI 0.79 to 0.96, respectively. The CI was wider
or those with diabetes because of the smaller number of
articipants with diabetes and their smaller total numbers of
VD events.
We performed a new meta-analysis that added data from
hree trials performed specifically in patients with diabetes
JPAD, POPADAD, and ETDRS) (9,10,18) to the data
rom the subgroups of patients with diabetes from the six
rials included in the ATT meta-analysis (Fig. 1). Using a
andom-effects model, we found that aspirin was associated
ith a 9% decrease in risk of CHD events (nonfatal and
atal MI) that was not statistically significant (RR 0.91, 95%
igure 1. Meta-Analysis of Trials Examining the Effects of Aspirin
: Effect of aspirin on coronary heart disease events. Tests for heterogeneity: 28.
ests for heterogeneity: 212.48, P0.131, I235.9%. BMD indicates British Med
hy Study (18); HOT, Hypertension Optimal Treatment (14); JPAD, Japanese Primary
12); POPADAD, Prevention of Progression of Arterial Disease and Diabetes (10); PP
omen’s Health Study (17).I 0.79 to 1.05). We did not identify important heteroge- aeity (28.71, P0.367, I28.2%), but a large portion of
he summary estimate depended on the ETDRS trial.
xcluding this trial, the estimate of effect for CHD events
as smaller.
For stroke, our random-effects meta-analysis of the nine
rials found a reduction in the risk of stroke of 15% (RR
.85, 95% CI 0.66 to 1.11) that was not statistically
ignificant. There was some heterogeneity (212.48,
0.131, I235.9%). The results of these diabetes-specific
nalyses are consistent with the findings of the ATT
eta-analysis and suggest that aspirin likely produces a
odest reduction in CVD risk, but limitations in the
sk of Cardiovascular Disease Events in Patients With Diabetes
0.367, I28.2%. B: Effect of aspirin on risk of stroke in patients with diabetes.
octors (11); CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopa-
tion of Atherosclerosis with aspirin for Diabetes (9); PHS, Physicians’ Health Study
ary Prevention Project (15); TPT, Thrombosis Prevention Trial (13); and WHS,on Ri
71, P
ical D
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June 22, 2010:2878–86 Aspirin for Primary Prevention in Diabetesffect. We also do not have access to sufficient patient-level
ata in patients with diabetes to consider whether the effect
f aspirin on CHD events and stroke differs by sex, the dose
f aspirin used, or other clinical factors.
Other recent meta-analyses have examined the effect of
spirin on CVD events in patients with diabetes. DeBerardis
nd colleagues (19) included six of the nine trials included in
ur analysis (they did not include HOT, BMD, or TPT due to
ack of data on patients with diabetes in the original publica-
ions) and found estimates of effect with aspirin similar to those
f our analysis: for MI, RR 0.86 (95% CI 0.61 to 1.21) with
oderate heterogeneity (I262.2%), mainly due to inclusion
f WHS and PHS. For stroke, they included five trials
excluding PHS) and calculated a summary RR of 0.83 (95%
I 0.60 to 1.14) and also noted moderate heterogeneity
I252.5%), mainly due to inclusion of WHS. They also
dentified potentially important effect modification by sex:
spirin reduced MI for men (RR 0.57, 95% CI 0.34 to 0.94)
ut not for women (RR 1.08, 95% CI 0.71 to 1.65).
Zhang and colleagues (20) included seven trials in their
eta-analysis (they did not include BMD or TPT) and also
ound similar results (for MI, RR 0.85, 95% CI 0.65 to 1.11;
or stroke, RR 0.83, 95% CI 0.63 to 1.10). They performed
eta-regression and identified important differences in
utcomes by sex. They found no evidence of publication
ias based on funnel plots using Begg and Egger tests.
alvin and colleagues (21) included seven trials from our
eta-analysis of patients with diabetes (they did not include
PT or BMD) and for MI found RR 0.86 (95% CI 0.67 to
.11) using the seven trials. For ischemic stroke, they found
R 0.62 (95% CI 0.31 to 1.24) using only the results of
HS and JPAD for their analysis.
The trials pooled in all of the meta-analyses varied widely in
he CHD event rates in the control group. If the RR reduction
the metric being pooled) is consistent across patients of
iffering underlying absolute risk, as suggested by secondary
revention trials and the individual patient-level meta-analysis
5), then such analyses seem to be reasonable. Taken together,
he other meta-analyses reinforce our main findings: aspirin
ppears to produce a modest-sized reduction in MI and stroke
n patients with diabetes, but current evidence is not conclusive
ecause there have been too few events in the available trials to
recisely estimate its effects and because our findings rely on
nalyses of subgroups within larger trials, which have more
otential for bias. The currently available data also reinforce
hat the possible differences in outcomes for men and women
equire further study.
. What Are the Potential Harms of Aspirin,
nd Are These Similar or Different for
eople With Diabetes Compared to
hose Without?
he major adverse effects of aspirin therapy include intra-
ranial bleeding (hemorrhagic stroke) and extracranial tleeding, principally gastrointestinal. Based on data from
rimary and secondary prevention trials conducted in mixed
opulations of patients with and without diabetes, low-dose
spirin appears to be associated with an absolute risk of
emorrhagic stroke of 1 in 10 000 people annually (22).
nalyses that examined the primary prevention trials sepa-
ately have reached similar results (5,23). These hemor-
hagic strokes are incorporated in the estimate of the effect
f aspirin on all strokes considered above in question 2.
For extracranial (mainly gastrointestinal) bleeding, aspi-
in use is associated with a 54% increase in risk based on
eta-analysis of the six primary prevention trials (RR 1.54,
5% CI 1.30 to 1.82). The absolute increase in risk was on
he order of 3 in 10 000 per year in mainly middle-aged
dults enrolled in the aspirin primary prevention trials. The
TT collaboration authors found that several risk factors
or CVD also increased the risk for extracranial bleeding
rom aspirin, suggesting that those at higher CVD risk are
lso at higher risk for aspirin-related adverse effects. Those
ith diabetes taking aspirin experienced a 55% increased
isk (RR 1.55, 95% CI 1.13 to 2.14) compared with those
ithout diabetes (5). Since the primary prevention trials
sed by the ATT collaboration and by this meta-analysis
xcluded patients with a history of peptic ulcer disease, the
isk calculations for bleeding cannot be extended to that
opulation.
Notably, the absolute excess risk of gastrointestinal bleed-
ng with aspirin is likely higher among free-living older
dults, with rates of 1 to 10 per 1000 annually reported in a
arge cohort study (24). While evidence supports that use of
roton-pump inhibitors (PPIs) can decrease the risk of
ecurrent aspirin-related gastrointestinal bleeding (25), it is
ot clear whether routine use of a PPI is cost-effective or
hould be recommended for primary prevention of gastro-
ntestinal bleeding.
. What Do We Know About the
ecommended Dosage or Dosage Range?
he optimal dosage of aspirin for prevention of cardiovas-
ular events is not clearly established from the outcomes
iterature. The average daily dose used in the primary
revention trials involving participants with diabetes ranged
rom 50 to 650 mg daily (Table 1). Indirect evidence from
he ATT collaboration suggests that the risk reductions
chieved with low doses (75 to 162 mg/day) are as large as
hose obtained with higher doses (500 to 1500 mg/day) and
arger than those in the few trials that have used doses below
5 mg/day (26). The failure of higher doses to produce
reater reductions in thrombotic events may in part be due
o the fact that the inhibitory effects of aspirin on the
latelet are permanent. Thus, even low doses will achieve a
ull effect after several days of dosing. Additionally, the
ffects of aspirin begin in the portal circulation and are
hereby presystemic. This removes the variability of hepatic
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amic variability with other agents such as clopidogrel
27,28).
Although platelets from patients with diabetes have
ltered function, it is unclear what, if any, impact that
nding has on the required dose of aspirin for cardiopro-
ective outcomes in the diabetic patient (29). Many alternate
athways exist for platelet activation and aggregation (aden-
sine diphosphate, thrombin, epinephrine, von Willebrand
actor) that are independent of thromboxane A2 and thus
ot sensitive to the effects of aspirin (30). Therefore, while
spirin resistance appears higher in the diabetic patients
hen measured by a variety of ex vivo and in vitro methods
platelet aggregometry, measurement of thromboxane B2),
hese observations alone are insufficient to empirically rec-
mmend higher doses of aspirin be used in the diabetic
atient at this time (31–33).
. How Can We Integrate Potential Benefits
nd Harms of Aspirin to Determine Which
atients With Diabetes Should or Should
ot Receive Aspirin for the Primary
revention of CV Events?
ased on the currently available evidence, aspirin appears to
ave a modest effect on cardiovascular events (RR reduction
f 10%), with the absolute decrease in events depending
n the underlying CVD risk (those with higher baseline risk
hould have greater absolute benefit). The main adverse
ffects appear to be an increased risk of gastrointestinal
leeding. The excess risk may be as high as 1 to 5 per 1000
er year in real-world settings. In adults with CVD risk
reater than 1% per year, the number of CVD events
revented will be similar to or greater than the number of
leeding events induced, although the events considered
MI, stroke, and gastrointestinal bleeding) do not have
qual effects on long-term health (34). We have developed
ecommendations based on these data.
The effect of aspirin for primary prevention of CVD
vents in adults with diabetes is currently unclear. Trials to
ate have reached mixed results, but overall suggest that
spirin modestly reduces risk of cardiovascular events. More
esearch is needed to better define the specific effects of
spirin in diabetes, including any sex-specific differences.
or now, we recommend the following:
• Low-dose (75 to 162 mg/day) aspirin use for preven-
tion is reasonable for adults with diabetes and no
previous history of vascular disease who are at in-
creased CVD risk (10 year risk of CVD events over
10%) and who are not at increased risk for bleeding
(based on a history of previous gastrointestinal bleed-
ing or peptic ulcer disease or concurrent use of other
medications that increase bleeding risk, such as
NSAIDS or warfarin). Those adults with diabetes at pincreased CVD risk include most men over age 50
years and women over age 60 years who have one or
more of the following additional major risk factors:
smoking, hypertension, dyslipidemia, family history of
premature CVD, and albuminuria. (ACCF/AHA
Class IIa, Level of Evidence: B) (ADA Level of
Evidence: C)
• Aspirin should not be recommended for CVD preven-
tion for adults with diabetes at low CVD risk (men under
age 50 years and women under 60 years with no major
additional CVD risk factors; 10-year CVD risk under
5%) as the potential adverse effects from bleeding offset
the potential benefits. (ACCF/AHA Class III, Level of
Evidence: C) (ADA Level of Evidence: C)
• Low-dose (75 to 162 mg/day) aspirin use for preven-
tion might be considered for those with diabetes at
intermediate CVD risk (younger patients with one or
more risk factors, or older patients with no risk factors,
or patients with 10-year CVD risk of 5% to 10%) until
further research is available. (ACCF/AHA Class IIb,
Level of Evidence: C) (ADA Level of Evidence: E)
ardiovascular Risk Assessment
hese recommendations depend on the accurate assessment
f cardiovascular risk as part of the decision-making process
bout aspirin use. All patients with diabetes do not have
igh cardiovascular risk, despite the assumptions of some
revious guidelines (35). We have provided treatment guid-
nce based on either a combination of age, sex, and other
isk factors or on an estimate of absolute cardiovascular risk.
n important consideration is that patients may acquire
dditional risk factors over time, which would necessitate a
eassessment of their overall risk profile. The absolute
isk-based recommendations require the use of a risk pre-
iction tool. Tools that can be used in patients with diabetes
re available from several sources, for example:
UKPDS Risk Engine:
http://www.dtu.ox.ac.uk/riskengine/index.php
ARIC CHD Risk Calculator:
http://www.aricnews.net/riskcalc/html/RC1.html
American Diabetes Association Risk Assessment Tool,
Diabetes PHD: http://www.diabetes.org/phd
oncurrent Therapies
hether patients have sufficient CVD risk to warrant
spirin use under these assumptions will also depend on the
se of other effective techniques for CVD risk reduction,
ncluding statins, blood pressure control, and smoking
essation (36,37). Each of these therapies also lowers the
isk of CVD events and should be considered when deciding
bout aspirin use. If these other effective treatments are
dopted first, then fewer patients with diabetes will remain
t sufficient risk to warrant aspirin use, in light of its
otential adverse effects. For example, a patient at 20%
1
m
1
e
a
r
i
r
d
6
T
t
c
a
P
l
m
d
e
s
o
y
A
D
w
p
e
e
2

0
d
b
i
d
C
t
w
A
r
d
3
8
p
t
t
c
p
p
p
w
c
t
m
s
a
H
r
p
i
p
A
T
g
M
f
R
M
i
r
r
i
R
1
2885JACC Vol. 55, No. 25, 2010 Pignone et al.
June 22, 2010:2878–86 Aspirin for Primary Prevention in Diabetes0-year risk based on elevated blood pressure and subopti-
al lipid levels would have his risk reduced from 20% to
3% by taking a statin and from 13% to 10% based on
ffective blood pressure control, which makes the decision
bout whether to take aspirin more complex. Although the
isk reduction with these additional therapies does not occur
mmediately, their effects can be assumed to occur with
apidity sufficient to incorporate them in the initial
ecision-making process.
. What Are the Needs for Future Research?
wo ongoing studies will provide additional information on
he role of low-dose aspirin for the prevention of cardiovas-
ular events specifically in patients with diabetes. Aspirin
nd Simvastatin Combination for Cardiovascular Events
revention Trial in Diabetes (ACCEPT-D) is an open-
abel Italian primary prevention trial comparing aspirin 100
g daily to no aspirin among adults over age 50 years with
iabetes who are also taking simvastatin (38). The planned
nrollment is 5170, and the investigators will examine
everal prespecified subgroups to detect differences in effect
f aspirin, including men versus women and older versus
ounger age, as well as baseline lipid levels and use of statins.
second trial, A Study of Cardiovascular Events in
iabetes (ASCEND), is being conducted in the U.K. and
ill also examine the effects of 100 mg aspirin daily versus
lacebo among men and women over age 40 years who have
ither type 1 or type 2 diabetes but no previous vascular
vents (39). It uses a double-blind placebo-controlled and
 2 factorial design that will also examine the effects of
-3 fatty acid supplements. The planned enrollment is 10
00, which was designed to provide adequate power to
etect a 20% reduction in major vascular events including
oth MI and stroke.
Although these trials will provide important additional
nformation, it is possible that they will not definitively
etermine whether aspirin is effective for prevention of
HD events in people with diabetes. This may be especially
rue for important subgroups such as patients on statins,
omen, and patients with type 1 diabetes. Although
SCEND is powered for a 20% RR reduction, an RR
eduction of 10% among patients with an underlying inci-
ence of 10% in the control group would require over
6 000 participants if 90% power is desired and 26 000 for
0% power. To achieve this event rate among moderate-risk
atients with diabetes (annual event rates of 1% to 2%), a
rial would need to be 5 to 10 years in duration. Thus, while
he ongoing trials may not provide definitive answers, their
ombined enrollment of over 15 000 patients will add im-
ortant new information on the role of aspirin for primary
revention in patients with diabetes.
In addition, development of reliable surrogate testing for
latelet reactivity and response to antiplatelet therapies
ould be helpful in the management of patients for whom
1oncerns have been raised about aspirin resistance, such as
hose with diabetes (27,28). Such testing could also allow
ore precise determination of the dose-response relation-
hip for aspirin in patients both with and without diabetes
nd better inform the design of large outcomes studies.
owever, while some encouraging epidemiologic and ret-
ospective data exists for current methods of surrogate
latelet testing for aspirin, these data lack sufficient rigor to
nform clinical decision making, particularly in the setting of
rimary prevention (32,33,40).
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